HomeProgram ▶ Non-CME Symposia
Non-CME Symposia

The ATS encourages Non-CME Symposia in conjunction with the International Conference. All full-conference participants are encouraged to attend these programs.

Sunday, May 21, 6:30 - 9:30 p.m.

Embassy Suites DC Convention Center

Capital Ballroom
(Lower Lobby)
Treating Symptomatic Sarcoidosis: An Interactive Case Discussion (Open to U.S. attendees only)

Sarcoidosis is a chronic inflammatory granulomatous disease that typically affects the lungs, but frequently includes extrapulmonary manifestations. This dinner program will address the significant unmet need in the treatment of symptomatic sarcoidosis, introduce the melanocortin receptor system as a therapeutic area, and feature an interactive discussion around symptomatic sarcoidosis patient cases. Supported and presented by Mallinckrodt Pharmaceuticals, Inc.
Company: Mallinckrodt Pharmaceuticals, Inc

Grand Hyatt Washington

Independence Ballroom A
(Independence Level 5B)
IPF Hackathon: Disrupting and Evolving the Management of IPF (Open to U.S. attendees only)

Engage in collaborative discussions with a team of expert Pulmonologists while investigating and discussing challenges in the management of IPF. In this interactive symposium, actively participate in timed, small group discussions designed to address and solve key issues around:

  • Barriers to treating IPF patients upon diagnosis
  • Better preparing patients to live with an IPF diagnosis
  • Providing IPF patients with the tools and resources needed to commit to a shared physician-patient partnership

Speakers: Steven Nathan, MD Inova Fairfax Hospital Falls Church, VA; Robert Sussman, MD Overlook Medical Center Summit, NJ; Rajeev Saggar, MD University of Arizona – College of Medicine Tuscon, AZ
Company: Genentech, A Member of the Roche Group

Independence Ballroom B-E
(Independence Level 5B)
Chronic Use of Oral Corticosteroids in Asthma: Will Biologics End This?(Open to International attendees only)

Patients with severe asthma are frequently prescribed oral corticosteroids (OCS), despite the evidence that prolonged use of OCS is associated with potentially serious adverse events. This Novartis-sponsored symposium will focus on alternative treatments, such as biologics, which can reduce the reliance on OCS in severe allergic asthma patients. How a phenotype-driven approach to treatment may aid in the prevention of the chronic use of OCS in severe asthma will also be discussed. Please note that this symposium is for non-US HCPs only

Speakers: Roland Buhl, MD, PhD, Professor, Johannes Gutenberg University of Mainz; Guy Brusselle, MD, PhD, FERS, Professor, Department of Respiratory Medicine, Ghent University Hospital; Ulrich Hans Wahn, MD, FRCP, Professor, Charité-Universitätsmedizin Berlin; Jean Bousquet, MD, PhD, Professor.
Company: Novartis Pharma AG

Independence Ballroom F-I
(Independence Level 5B)
Diagnosing and Managing NTM in the Community Setting

NTM (non-tuberculous mycobacterial) pulmonary disease is a chronic and debilitating infection. Diagnosis can be challenging as the signs and symptoms of NTM pulmonary disease are non-specific and similar to existing structural lung diseases of NTM patients, such as bronchiectasis and COPD. Additionally, the decision to treat is multi-factorial and requires an individualized and patient-centered approach. This symposium will explore the approaches of managing NTM in the community setting, using case discussions to highlight considerations for identifying patients at risk for NTM, diagnosing NTM, initiating treatment, and ongoing monitoring of patient responses to treatment.  Register here:

Chair: Anne O'Donnell, MD, Chief, Pulmonary, Critical Care and Sleep Medicine, Georgetown University Hospital
Speakers: Shannon Kasperbauer, MD, Assistant Professor, Division of Mycobacterial and Respiratory Infections, National Jewish Health
Patrick Flume, MD, Powers-Huggins Endowed Chair for Cystic Fibrosis, Professor of Medicine and Pediatrics, Medical University of South Carolina
Company: Insmed

Constitution Ballroom A-B
(Constitution Level 3B)
Redefining Severe Uncontrolled Asthma: A Fresh Look at a Complex Disease

You are cordially invited to an AstraZeneca sponsored non-CME dinner program on severe uncontrolled asthma. This faculty led symposium will examine asthma heterogeneity and the burden of disease from the phenotype / endotype perspective to demonstrate the importance of relating observable characteristics to disease mechanisms in clinical settings. The presentation will include a detailed discussion of eosinophils as an emerging mechanism of disease and review current evidence linking eosinophilic activity to many of the characteristic features of severe uncontrolled asthma.

Speakers: Nicola Hanania, MD, MS, Associate Professor of Medicine, Director, Airways Clinical Research Center, Baylor College of Medicine; Jonathan A. Bernstein, MD, Professor of Clinical Medicine, University of Cincinnati, Department of Internal Medicine, Division of Immunology/Allergy Section; Thomas B. Casale, MD, Professor of Medicine and Pediatrics, University of South Florida Morsani College of Medicine; Michael Wechsler, MD, MMSc, Professor of Medicine, Co-Director National Jewish Cohen Family Asthma Institute, National Jewish Health
Company: AstraZeneca

Constitution Ballroom C-E
(Constitution Level 3B)
Clinicians’ Review: A Case-Based Look at Diagnosing and Treating Patients with IPF

During this branded symposium, relevant case studies will be delivered from the perspective of pulmonologists experienced in the diagnosis and management of patients with IPF. The treatment of these patients will also be discussed. Interactive Q&A and audience response system will be utilized throughout the program.

Speakers: Lucas Ryan Pitts, MD, FCCP Assistant Professor, Pulmonary and Critical Care Medicine, University of Kansas Medical Center;  Nina Patel, MD Assistant Professor of Medicine
Co-Director, Columbia University Interstitial Lung Disease Program, Division of Pulmonary, Allergy & Critical Care, Columbia University

Company: Boehringer Ingelheim Pharmaceuticals, Inc.

Renaissance Washington DC Dupont Circle

City Center Ballroom
(Lower Lobby Level)
Biologics and Immune Therapies in an Office Setting – Optimizing Treatment and Outcomes Through Patient-Centered Care

This Complimentary Dinner Symposium will outline the merits of establishing allergy and immunology office-based administration of therapies and the steps required. Three expert faculty will facilitate an interactive discussion of injectable and infused therapies in the pulmonology, allergy, and immunology settings and their roles in treatment. Additionally, patient-centered benefits of office-based administration and operational strategies for establishing an in-office infusion practice will also be highlighted throughout the symposium via collaborative panel and audience discussions. Register here:

Speakers: Gregory Bensch, MD, Allergy Immunology and Asthma Group, Stockton, California; Bradley E. Chipps, MD, Medical Director
Capital Allergy & Respiratory Disease Center, Sacramento, CA; Josh Jacobs, MD Allergy & Asthma medical Group of the Bay Area, Berkely, California
Company: Academy for Continued Healthcare Learning
(supported by an educational grant from Teva Pharmaceuticals)

Washington Marriott at Metro Center

Grand Ballroom A-D
(Ballroom Level)
PAH Combination Therapy: Targeting Multiple Pathways to Optimize Treatment

The management of pulmonary arterial hypertension (PAH) continues to evolve, with combination therapy that targets multiple pathways now at the forefront of our treatment strategies. This interactive symposium will feature a panel of experts who will discuss treatment options for patients with PAH.
Dinner will be provided. Dinner will not be provided to physicians and other healthcare professionals licensed in Vermont or other states where gifts and meals are prohibited.

Speakers: Vallerie Mclaughlin, MD, Program Chair, University of Michigan Health System, Ann Arbor, Michigan; Nick Kim, MD, University of California, San Diego, La Jolla, California; Ronald Oudiz, MD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California
Company: Actelion Pharmaceuticals US, Inc.

Junior Ballroom
(Second Floor)
The 2017 GOLD Update: Incorporating the New Treatment Recommendations into Clinical Practice (Open to U.S. attendees only)

GOLD recently released an updated strategy for management of COPD based on expert opinion and current data. Experts will review the 2017 update and discuss implications of GOLD recommendations on clinical practice, with a focus on the refined ABCD assessment tool and treatment algorithm. Panelists and attendees will interactively examine patient cases, demonstrating applicability of GOLD treatment recommendations in real-world settings.

Speakers: Fernando J. Martinez, MD, MS, Chief, Division of Pulmonary and Critical Care Medicine, New York‐Presbyterian Hospital/Weill Cornell Medical Center Claus Vogelmeier. Prof. Dr. med., Professor of Medicine and Head of the Department for Pulmonary Medicine, Philipps‐University of Marburg, Germany; Prof. Christine Jenkins, MD, Clinical Professor and Head of Respiratory Discipline, University of Sydney, Sydney, NSW, Australia; Gerard Criner, MD, Chair and Professor, Thoracic Medicine and Surgery, Temple University
Company: Boehringer Ingelheim Pharmaceuticals, Inc.

Westin Washington DC City Center

National Ballroom
(Ballroom Level)
Clinically Refractory Hypotension (CRH): Evolution of Shock Management

The goal of this program is to provide an overview of different forms of shock, current management strategies, and outcomes associated with hypotension. It will focus on a subset of patients who remain refractory despite adequate fluid resuscitation and high dose vasopressors. Management strategies and current therapeutic outcomes will also be discussed.

Speakers: Timothy E. Albertson MD, PhD, Professor & Chair, Dept. of Internal Medicine, UC Davis; Adan (Adam) Mora MD, FCCP, Assistant Clinical Professor, Texas A&M Health Science Center, Medical Director & Chief of Staff, Select Specialty Hospital, Dallas Downtown; Aaron Strumwasser MD, M.SC., Assistant Professor of Clinical Surgery, LA County, USC Medical Center
Company: La Jolla Pharmaceutical Company

Tuesday, May 23, 6:30 - 9:30 p.m.

Grand Hyatt Washington

Independence Ballroom A
(Independence Level 5B)
Understanding and Implementing New Advances in Idiopathic Pulmonary Fibrosis Management: Practical Guidance for Everyday Care

This interactive and dynamic educational symposium will combine focused interpretations of the latest clinical data and consensus guidelines by top experts in the field with engaging discussions about clinical challenges, real-world patient scenarios, and strategies to improve the management of IPF and disease-associated comorbidities. Register here:

Speakers: Steven D. Nathan, MD, Medical Director, Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Professor of Medicine, Virginia Commonwealth University-Inova Fairfax Campus, Falls Church, VA; Paul W. Noble, MD, Professor and Chair, Department of Medicine, Director, Women’s Guild Lung Institute, Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; David A. Lynch, MB, Professor, Department of Radiology, National Jewish Health, Denver, CO
Company: PVI, PeerView Institute for Medical Education (Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.)
Independence Ballroom B-E
(Independence Level 5B)
Treating Adults With Severe, Uncontrolled Eosinophilic Asthma (In compliance with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs) 

A review of considerations in the diagnosis and management of eosinophilic asthma.

Speakers: Kevin R. Murphy, MD, Director, Clinical Research Allergy, Asthma and Pediatric Pulmonology, Boys Town National Research Hospital, Omaha, Nebraska; PHIL LIEBERMAN, MD, Clinical Professor of Medicine and Pediatrics, University of Tennessee College of Medicine, Memphis, Tennessee

Company: Teva Respiratory, LLC.

Independence Ballroom F-I
(Independence Level 5B)
Nasal High Flow: Evidence and Equipoise 

The potential for Nasal High Flow therapy to provide both preventative and restorative respiratory support has been validated with the emergence of robust evidence within the of the fields of respiratory and critical care medicine and beyond. The three speakers are all accomplished investigators from the critical care field. They will bring knowledge and perspective that will help inform future practice in respiratory support medicine.

Speakers: Jean-Pierre Frat, MD, Dr, Centre Hospitalier Universitaire de Poitiers Poitiers France; Gonzalo Hernandez, MD, PhD, Dr, Hospital Infanta Sofi Madrid Spain;  Tommaso Mauri, MD, Dr, University of Milan, Milano Italy
Company: Fisher & Paykel Healthcare Ltd.

Constitution Ballroom A-B
(Constitution Level 3B)
Optimal bronchodilation in COPD: Evolving the paradigm (Open to International attendees only)

The symposium will review the GOLD 2017 treatment algorithms; discuss the contribution of dual bronchodilation in
personalized medicine, the latest evidence and treatment implications in real life settings as well as the role of ICS in COPD
management. Please note that this symposium is sponsored by Novartis Pharma AG and is for non-US HCPs only.

Speakers: Bartolome Celli, MD, Professor, Harvard Medical School, USA; David Halpin, MA, DPhil, MB BS, FRCP, Professor, Royal
Devon & Exeter Hospital, UK; Maria Victorina López Varela, MD, Professor, Universidad de la República, Montevideo,
Uruguay; David Price, MBBChir, MA, FRCGP, Professor, Observational and Pragmatic Research Institute (OPRI), Singapore

Company: Novartis Pharma AG

Constitution Ballroom C-E
(Constitution Level 3B)
Duchenne Muscular Dystrophy (DMD): Importance of Preserving Pulmonary Function and Impact of Idebenone (An Investigational Treatment) in Boys with DMD

Please join us for an informative session on one of the most common and devastating types of muscular degeneration, Duchenne Muscular Dystrophy (DMD). This expert panel will review: pathophysiology of DMD, data from DMD natural history study (CINRG), data around the importance of preserving pulmonary function in DMD, as well as data for idebenone (Raxone)-a new treatment option in development for DMD by Santhera Pharmaceuticals.

Speakers: Oscar Henry Mayer, MD Division of Pulmonary Medicine Medical Director, Pulmonary Function Testing Laboratory The Children’s Hospital of Philadelphia Associate Professor of Clinical Pediatrics Perelman School of Medicine at the University of Pennsylvania; Erik Henricson, PhD, MPH Assistant Professor Associate Director for Clinical Research UC Davis Department of Physical Medicine & Rehabilitation Neuromuscular Research Center; Hemant Sawnani, M.D. Associate Professor, Division of Pulmonary Medicine, Section of Sleep Medicine Comprehensive Neuromuscular Program Cincinnati Children’s Hospital Medical Medical Center 
Company: Santhera Pharmaceuticals (USA), Inc.

Renaissance Washington Downtown

Grand Ballroom
(Ballroom Level)
Are You There Yet? 5 Things You Need to Know About IPF in 2017

Wrap up your ATS experience with a pre-meeting social event. Relax and challenge your friends and colleagues in an IPF contest before we begin. Then join Drs. Kevin Flaherty, Fernando Martinez, and David Lederer as they dive into the latest evidence in diagnostics, emerging therapies, and genomics. They will also share their current experience with clinical cases. Register at

Speakers: Kevin R. Flaherty, MD, MS, Professor, Division of Pulmonary and Critical Care Medicine, University of Michigan Health System; Fernando J. Martinez, MD, MS, Chief, Division of Pulmonary and Critical Care Medicine, New York Presbyterian Hospital/ Weill Cornell Medical Center; David J Lederer, MD, MS, Associate Professor, Columbia University Medical Center
Company: The France Foundation
(supported by a grant from Genentech, Inc.)

Renaissance Ballroom
(Ballroom Level)
The Evolution of Asthma Guidelines: Moving Towards Personalized Treatment (Open to U.S. attendees only)

There has been no update to the U.S. (NHLBI) asthma treatment guidelines for a decade. This event will include a presentation reviewing the major evolution of treatment evidence since the last published guidelines (2007) and include a discussion /debate regarding how this evidence might inform future US guidelines.

Speakers: William Busse, MD Professor Division of Allergy and Immunology, Department of Medicine University of Wisconsin School of Medicine and Public Health; Monica Kraft, MD Chair, Department of Medicine, Asthma and Airway Diseases Research Center University of Arizona Health Sciences Center; Michael Wechsler, MD, MMSc Co-Director, The Cohen Family Asthma Institute, Professor Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine National Jewish Health
Company: Boehringer Ingelheim Pharmaceuticals, Inc.

Washington Marriott at Metro Center

Grand Ballroom A-D
(Ballroom Level)
To Use or Not to Use ICS: The Shifting Paradigm in COPD

Learn about the use of ICS in COPD while challenging your friends and colleagues in fun games. Interactive case-based discussions using iPads including clinical scenarios in which, based on current evidence and/or recommendations, ICS should or should not be considered. Register at

Speakers: Gary T. Ferguson, MD, Pulmonary Research Institute of Southeast Michigan; James F. Donohue, MD, Professor, University of North Carolina School of Medicine; Nicola Alexander Hanania, MBBS, Associate Professor, Baylor College of Medicine
Company: The France Foundation
(supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.)

Junior Ballroom (Second Floor) Clinical Issues in Severe Asthma: Consensus and Controversies on the Road to Precision Medicine
Patients with severe asthma suffer from an outsized proportion of morbidity and mortality associated with this disease. However, improved understanding of asthma pathophysiology and disease phenotypes have paved the way for new treatment strategies and the potential for better long-term patient outcomes. In this Clinical Issues™ program, expert faculty will discuss and debate a series of topics related to the management of severe asthma, including disease classification, biomarkers, comorbidity management, and current and emerging targeted biologic therapies, all shaped by new findings presented at the American Thoracic Society’s 113th Annual Conference. Attendees are sure to leave this lively and engaging program with a fresh perspective on evolving management paradigms for severe asthma.

Speakers: Reynold A. Panettieri, Jr., MD, Professor of Medicine, Robert Wood Johnson Medical School, Vice Chancellor, Clinical & Translational Science, Director, Rutgers Institute for Translational Medicine & Science, Emeritus Professor of Medicine, University of Pennsylvania ; Sally E. Wenzel, MD, Professor of Medicine, Director, University of Pittsburgh Asthma Institute @UPMC/UPSOM, UPMC Chair in Translational Airway Biology, Subsection Chief of Allergy, Pulmonary, Allergy and Critical Care Medicine; Eugene R. Bleecker, MD, Professor and Co-Chief, Division of Genetics, Genomics, and Precision Medicine Department of Medicine, Co-Director, Division of Pharmacogenomics Center for Applied Genetics and Genomics Medicine, University of Arizona College of Medicine, Tucson, Arizona
Company: Integritas Communications and The Elsevier Office of Continuing Medical Education (EOCME)  
(supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals)